2
|
Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California. Am J Obstet Gynecol 2021; 225:656.e1-656.e11. [PMID: 34273278 DOI: 10.1016/j.ajog.2021.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 06/30/2021] [Accepted: 07/12/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The risk of a high-grade lesion in women undergoing colposcopy following an abnormal screening result may be different by human papillomavirus vaccination status, because women who are vaccinated are presumably less likely to harbor human papillomavirus types 16 and 18. OBJECTIVE This study aimed to evaluate whether the risk of high-grade cervical lesion diagnosed through colposcopy is lower in women with human papillomavirus vaccination than in women without vaccination referred to colposcopy based on equal abnormal screening findings. STUDY DESIGN Kaiser Permanente Orange County female patients between ages 21 and 38 years were included following an abnormal screening if they had ≥1 colposcopies between July 2017 and August 2018 and had at least 1 pathology diagnosis from the colposcopy visits. Data on demographic characteristics, clinical and sexual histories, and human papillomavirus vaccination were collected using a colposcopy registry smart form and from electronic medical records. Human papillomavirus genotyping was performed for tissues from confirmed cervical intraepithelial neoplasm grade 2+ diagnoses. A multilevel generalized linear model with a logic function was used to evaluate the association between human papillomavirus vaccination history and the outcome of a cervical intraepithelial neoplasm grade 2+ diagnosis and for human papillomavirus type 16- or 18-positive cervical intraepithelial neoplasm grade 2+ as an alternative outcome, adjusting for screening results and potential confounders. RESULTS Of 730 women included in the study, 170 had a histologic diagnosis of cervical intraepithelial neoplasm grade 2+ (23.2%). Moreover, 68 cases (40.0%) were histologically human papillomavirus type 16 and/or 18 positive. Of the 730 women, 311 (43%) were vaccinated for the human papillomavirus before colposcopy. Most women (206 [66.2%]) with human papillomavirus vaccination received the vaccine between the ages 18 and 26 years. A history of human papillomavirus vaccination overall, before sexual debut, before the age of 18 years, or with complete dosing was not associated with lower odds of a cervical intraepithelial neoplasm grade 2+ diagnosis (odds ratio, 1.07 [95% confidence interval, 0.70-1.64]; odds ratio, 1.11 [95% confidence interval, 0.55-2.24]; odds ratio, 0.96 [95% confidence interval, 0.49-1.91]; and odds ratio, 0.84 [95% confidence interval, 0.53-1.35], respectively, in reference to no vaccination). Human papillomavirus vaccination history was not significantly associated with the odds of a human papillomavirus type 16- or 18-positive cervical intraepithelial neoplasm grade 2+ diagnosis (P=.45). Notably, 8 cases (4.8% of all cervical intraepithelial neoplasm grade 2+ cases) showed a human papillomavirus type 16 on a cervical intraepithelial neoplasm grade 2+ histologic polymerase chain reaction analysis despite reported or documented human papillomavirus vaccination before sexual debut, including 2 cases who started vaccination before the age of 13 years. CONCLUSION Our study did not support modifying the colposcopy management guidelines for abnormal screening results for women with human papillomavirus vaccination, especially those vaccinated in the catch-up age range. Our findings on the 8 cases of human papillomavirus 16-positive cervical intraepithelial neoplasm grade 2+ vaccination before sexual debut suggested that lowering the recommended age for human papillomavirus vaccination may have additional benefits for preventing human papillomavirus infection that could occur early in life in some women.
Collapse
|
3
|
Abstract
The most effective strategy for cervical cancer prevention involves vaccination to prevent human papillomavirus (HPV) infections during adolescence followed by screening to detect HPV infections during adulthood. HPV vaccination before sexual debut can prevent HPV infections, precancers, and cancers. HPV vaccination of sexually active populations does not prevent cancer. Screening with HPV testing is the most effective method of detecting precancers and cancers between ages 25 and 65. Ensuring adequate screening around the age of menopause may be the key to preventing cervical cancer among elderly women. Most cervical cancers at all ages occur among unscreened or underscreened women.
Collapse
Affiliation(s)
- Terresa J Eun
- Department of Sociology, Stanford University, 120, 450 Serra Mall Wallenberg, Stanford, CA 94305, USA; Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street, 6th Floor, Boston, MA 02118, USA
| | - Rebecca B Perkins
- Department of Sociology, Stanford University, 120, 450 Serra Mall Wallenberg, Stanford, CA 94305, USA; Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston Medical Center, 85 East Concord Street, 6th Floor, Boston, MA 02118, USA.
| |
Collapse
|
8
|
Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34:1803-12. [PMID: 27069078 DOI: 10.1200/jco.2016.67.2014] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
American Society of Clinical Oncology (ASCO), the leading medical professional oncology society, is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention. As the main providers of cancer care worldwide, our patients, their families, and our communities look to us for guidance regarding all things cancer related, including cancer prevention. Through this statement and accompanying recommendations, ASCO hopes to increase awareness of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the discussion of HPV vaccination on its likely ability to prevent millions of cancer deaths, and increase HPV vaccination uptake via greater involvement of oncology professionals in ensuring accurate public discourse about HPV vaccination and calling for the implementation of concrete strategies to address barriers to vaccine access and acceptance.
Collapse
Affiliation(s)
- Howard H Bailey
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR.
| | - Linus T Chuang
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Nefertiti C duPont
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Cathy Eng
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Lewis E Foxhall
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Janette K Merrill
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Dana S Wollins
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| | - Charles D Blanke
- Howard H. Bailey, University of Wisconsin Carbone Cancer Center, Madison, WI; Linus T. Chuang, Mount Sinai School of Medicine, New York, NY; Nefertiti C. duPont, Gynecologic Surgeons of North Houston, Shenandoah; Cathy Eng and Lewis E. Foxhall, MD Anderson Cancer Center, Houston, TX; Janette K. Merrill and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; and Charles D. Blanke, Oregon Health and Science University, Portland, OR
| |
Collapse
|